In this review article an exclusive experimental model of idiotypic vaccination and antiidiotypic therapy mediated by antibodies representing the internal image of a yeast killer toxin characterized by the broad spectrum of antimicrobial activity is discussed. The experimental model is based upon the physiological antibody immune response elicited during natural infections caused by microorganisms expressing specific yeast killer toxin cell wall receptors. Parenteral and mucosal idiotypic vaccination carried out by using a monoclonal antibody neutralizing the yeast killer toxin has shown to be effective against systemic and vaginal candidiasis. Polyclonal, monoclonal and recombinant antiidiotypic and human natural antireceptor antibodies internal image of the yeast killer toxin demonstrated to confer passive immunoprotection in experimental models of candidiasis and pneumocystosis and to kill in vitro multidrug resistant strains of Mycobacterium tuberculosis. The experimental model of idiotypic vaccination and antiidiotypic therapy may represent an opportunity for the prophylaxis and control of important infectious diseases which are not currently preventable by conventional vaccinal and therapeutic approaches.
|Number of pages||8|
|Issue number||SUPPL. 1|
|Publication status||Published - Jul 1999|
ASJC Scopus subject areas
- Public Health, Environmental and Occupational Health